This report evaluates ImmunityBio, Inc. (IBRX), a biotechnology company focused on immunotherapy development, against Shariah compliance standards. Key concerns arise from an exceptionally high interest income ratio due to minimal operating revenue, despite compliant debt and liquidity metrics. Business activities in healthcare R&D are permissible, with no non-compliant revenue streams identified. Overall, the company fails financial screening thresholds, leading to non-compliance across major indices. Investors may consider monitoring for revenue growth to improve future compliance.